A rapid bioluminescence assay for measuring myeloperoxidase activity in human plasma

Reece J. Goiffon; Sara C. Martinez; David Piwnica-Worms

doi:10.1038/ncomms7271

A rapid bioluminescence assay for measuring myeloperoxidase activity in human plasma

Reece J. Goiffon, Sara C. Martinez, David Piwnica-Worms

Research output: Contribution to journal › Article › peer-review

46 Scopus citations

Abstract

Myeloperoxidase (MPO) is a circulating cardiovascular disease (CVD) biomarker used to estimate clinical risk and patient prognosis. Current enzyme-linked immunosorbent assays (ELISA) for MPO concentration are costly and time-intensive. Here we report a novel bioluminescence assay, designated MPO activity on a polymer surface (MAPS), for measuring MPO activity in human plasma samples using the bioluminescent substrate L-012. The method delivers a result in under an hour and is resistant to confounding effects from endogenous MPO inhibitors. In a pilot clinical study, we compared MAPS and two clinical ELISAs using 72 plasma samples from cardiac catheterization patients. Results from parallel MAPS and ELISAs were concordant within 2±11 1/4g l 1 MPO with similar uncertainty and reproducibility. Results between parallel MAPS and ELISA were in better agreement than those between independent ELISAs. MAPS may provide an inexpensive and rapid assay for determining MPO activity in plasma samples from patients with CVD or potentially other immune and inflammatory disorders.

Original language	English (US)
Article number	6271
Journal	Nature communications
Volume	6
DOIs	https://doi.org/10.1038/ncomms7271
State	Published - Feb 10 2015

ASJC Scopus subject areas

General Chemistry
General Biochemistry, Genetics and Molecular Biology
General Physics and Astronomy

Access to Document

10.1038/ncomms7271

Cite this

@article{c887a4ce64de47b3b686adae075bf284,

title = "A rapid bioluminescence assay for measuring myeloperoxidase activity in human plasma",

abstract = "Myeloperoxidase (MPO) is a circulating cardiovascular disease (CVD) biomarker used to estimate clinical risk and patient prognosis. Current enzyme-linked immunosorbent assays (ELISA) for MPO concentration are costly and time-intensive. Here we report a novel bioluminescence assay, designated MPO activity on a polymer surface (MAPS), for measuring MPO activity in human plasma samples using the bioluminescent substrate L-012. The method delivers a result in under an hour and is resistant to confounding effects from endogenous MPO inhibitors. In a pilot clinical study, we compared MAPS and two clinical ELISAs using 72 plasma samples from cardiac catheterization patients. Results from parallel MAPS and ELISAs were concordant within 2±11 1/4g l 1 MPO with similar uncertainty and reproducibility. Results between parallel MAPS and ELISA were in better agreement than those between independent ELISAs. MAPS may provide an inexpensive and rapid assay for determining MPO activity in plasma samples from patients with CVD or potentially other immune and inflammatory disorders.",

author = "Goiffon, {Reece J.} and Martinez, {Sara C.} and David Piwnica-Worms",

note = "Funding Information: We would like to thank Brandon Rogalski for his assistance in characterizing MPO bioluminescence in plasma. We also thank Sharon Cresci for her assistance with the clinical protocol. This project was supported in part by National Institutes of Health Grant P50 CA94056. Additional funding was provided by award number F30 HL107009 (R.J.G.) and T32 HL007081 (S.C.M.) from the National Heart, Lung, and Blood Institute. Funding Information: We would like to thank Brandon Rogalski for his assistance in characterizing MPO biolumine scence in plasma. We also thank Sharon Cresci for her assistance with the clinical protocol. This project was supported in part by National Institutes of Health Grant P50 CA94056. Additional funding was provided by award number F30 HL107009 (R.J.G.) and T32 HL007081 (S.C.M.) from the National Heart, Lung, and Blood Institute.",

year = "2015",

month = feb,

day = "10",

doi = "10.1038/ncomms7271",

language = "English (US)",

volume = "6",

journal = "Nature communications",

issn = "2041-1723",

publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - A rapid bioluminescence assay for measuring myeloperoxidase activity in human plasma

AU - Goiffon, Reece J.

AU - Martinez, Sara C.

AU - Piwnica-Worms, David

N1 - Funding Information: We would like to thank Brandon Rogalski for his assistance in characterizing MPO bioluminescence in plasma. We also thank Sharon Cresci for her assistance with the clinical protocol. This project was supported in part by National Institutes of Health Grant P50 CA94056. Additional funding was provided by award number F30 HL107009 (R.J.G.) and T32 HL007081 (S.C.M.) from the National Heart, Lung, and Blood Institute. Funding Information: We would like to thank Brandon Rogalski for his assistance in characterizing MPO biolumine scence in plasma. We also thank Sharon Cresci for her assistance with the clinical protocol. This project was supported in part by National Institutes of Health Grant P50 CA94056. Additional funding was provided by award number F30 HL107009 (R.J.G.) and T32 HL007081 (S.C.M.) from the National Heart, Lung, and Blood Institute.

PY - 2015/2/10

Y1 - 2015/2/10

N2 - Myeloperoxidase (MPO) is a circulating cardiovascular disease (CVD) biomarker used to estimate clinical risk and patient prognosis. Current enzyme-linked immunosorbent assays (ELISA) for MPO concentration are costly and time-intensive. Here we report a novel bioluminescence assay, designated MPO activity on a polymer surface (MAPS), for measuring MPO activity in human plasma samples using the bioluminescent substrate L-012. The method delivers a result in under an hour and is resistant to confounding effects from endogenous MPO inhibitors. In a pilot clinical study, we compared MAPS and two clinical ELISAs using 72 plasma samples from cardiac catheterization patients. Results from parallel MAPS and ELISAs were concordant within 2±11 1/4g l 1 MPO with similar uncertainty and reproducibility. Results between parallel MAPS and ELISA were in better agreement than those between independent ELISAs. MAPS may provide an inexpensive and rapid assay for determining MPO activity in plasma samples from patients with CVD or potentially other immune and inflammatory disorders.

AB - Myeloperoxidase (MPO) is a circulating cardiovascular disease (CVD) biomarker used to estimate clinical risk and patient prognosis. Current enzyme-linked immunosorbent assays (ELISA) for MPO concentration are costly and time-intensive. Here we report a novel bioluminescence assay, designated MPO activity on a polymer surface (MAPS), for measuring MPO activity in human plasma samples using the bioluminescent substrate L-012. The method delivers a result in under an hour and is resistant to confounding effects from endogenous MPO inhibitors. In a pilot clinical study, we compared MAPS and two clinical ELISAs using 72 plasma samples from cardiac catheterization patients. Results from parallel MAPS and ELISAs were concordant within 2±11 1/4g l 1 MPO with similar uncertainty and reproducibility. Results between parallel MAPS and ELISA were in better agreement than those between independent ELISAs. MAPS may provide an inexpensive and rapid assay for determining MPO activity in plasma samples from patients with CVD or potentially other immune and inflammatory disorders.

UR - http://www.scopus.com/inward/record.url?scp=84955446924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955446924&partnerID=8YFLogxK

U2 - 10.1038/ncomms7271

DO - 10.1038/ncomms7271

M3 - Article

C2 - 25666092

AN - SCOPUS:84955446924

SN - 2041-1723

VL - 6

JO - Nature communications

JF - Nature communications

M1 - 6271

ER -

A rapid bioluminescence assay for measuring myeloperoxidase activity in human plasma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this